Global Information
회사소개 | 문의 | 비교리스트

알레르기성 비염 : 파이프라인 리뷰

Allergic Rhinitis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 232791
페이지 정보 영문 164 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


알레르기성 비염 : 파이프라인 리뷰 Allergic Rhinitis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 164 Pages

알레르기성 비염은 코를 통해 들어온 물질에 대해 면역 체계가 과잉반응할 때 일어나는 알레르기 반응입니다.

알레르기성 비염(Allergic Rhinitis) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 전해드립니다.

서론

  • 조사 범위

알레르기성 비염 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

알레르기성 비염 : 기업에서 개발중인 치료제

알레르기성 비염 : 대학/기관에서 연구중인 치료제

알레르기성 비염 : 파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

알레르기성 비염 : 기업에서 개발중인 제품

알레르기성 비염 : 대학/기관에서 연구중인 제품

알레르기성 비염 치료제 개발에 참여하고 있는 기업

  • 3M Drug Delivery Systems
  • Accolade Pharmaceuticals, LLC
  • Adamis Pharmaceuticals Corporation
  • AFFiRiS AG
  • ALK-Abello A/S
  • Ampio Pharmaceuticals, Inc.
  • AnaptysBio, Inc.
  • ASIT biotech s.a.
  • Axikin Pharmaceuticals, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Chrysalis BioTherapeutics, Inc.
  • ELORAC, Inc.
  • Faes Farma, SA
  • Fountain Biopharma Inc.
  • GenMont Biotech Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • HAL Allergy BV
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Hisamitsu Pharmaceutical Co., Inc.
  • J Uriach Y Compania, S.A.
  • Johnson & Johnson
  • Laboratorios LETI S.L.
  • Ligand Pharmaceuticals, Inc.
  • Marinomed Biotechnologie GmbH
  • Merck & Co., Inc.
  • Panmira Pharmaceuticals, LLC.
  • Pfizer Inc.
  • Protectimmun GmbH
  • Regeneron Pharmaceuticals, Inc.
  • RODES Inc.
  • Roxall Medizin GmbH
  • Sanofi
  • Shionogi & Co., Ltd.
  • Stallergenes SAS
  • Taiho Pharmaceutical Co., Ltd.
  • VentiRx Pharmaceuticals, Inc.
  • Xencor, Inc.
  • Ziarco Pharma Ltd

알레르기성 비염 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용요법 제품(Combination Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 프로파일

알레르기성 비염 : 최근의 파이프라인 동향

알레르기성 비염 : 휴지 상태인 프로젝트

알레르기성 비염 : 개발이 중지된 제품

알레르기성 비염 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 16.10.07

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Allergic Rhinitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Allergic Rhinitis - Pipeline by Advagene Biopharma Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by ALK-Abello AS, H1 2020
  • Allergic Rhinitis - Pipeline by Allovate LLC, H1 2020
  • Allergic Rhinitis - Pipeline by AOBiome LLC, H1 2020
  • Allergic Rhinitis - Pipeline by ASIT Biotech SA, H1 2020
  • Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, H1 2020
  • Allergic Rhinitis - Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Dobecure SL, H1 2020
  • Allergic Rhinitis - Pipeline by Emergo Therapeutics Inc, H1 2020
  • Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by HAL Allergy BV, H1 2020
  • Allergic Rhinitis - Pipeline by Inimmune Corp, H1 2020
  • Allergic Rhinitis - Pipeline by Inmunotek SL, H1 2020
  • Allergic Rhinitis - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Kolmar Korea Holdings Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Laboratorios LETI SL, H1 2020
  • Allergic Rhinitis - Pipeline by Link Health Group, H1 2020
  • Allergic Rhinitis - Pipeline by Marinomed Biotech AG, H1 2020
  • Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2020
  • Allergic Rhinitis - Pipeline by Navipharm Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Novartis AG, H1 2020
  • Allergic Rhinitis - Pipeline by Oneness Biotech Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H1 2020
  • Allergic Rhinitis - Pipeline by Sam-A Pharm Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Sedor Pharmaceuticals LLC, H1 2020
  • Allergic Rhinitis - Pipeline by Shouyao Holding Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Siolta Therapeutics Inc, H1 2020
  • Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H1 2020
  • Allergic Rhinitis - Pipeline by The Geneva Biotech Center SA, H1 2020
  • Allergic Rhinitis - Pipeline by United Biomedical Inc, H1 2020
  • Allergic Rhinitis - Pipeline by Vactech Oy, H1 2020
  • Allergic Rhinitis - Pipeline by Wolwo Pharma, H1 2020
  • Allergic Rhinitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..6), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..7), H1 2020
  • Allergic Rhinitis - Discontinued Products, H1 2020
  • Allergic Rhinitis - Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development for Allergic Rhinitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Pipeline Review, H1 2020, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 5, 12, 9, 2, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 5 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Allergic Rhinitis - Overview
  • Allergic Rhinitis - Therapeutics Development
  • Allergic Rhinitis - Therapeutics Assessment
  • Allergic Rhinitis - Companies Involved in Therapeutics Development
  • Allergic Rhinitis - Drug Profiles
  • Allergic Rhinitis - Dormant Projects
  • Allergic Rhinitis - Discontinued Products
  • Allergic Rhinitis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q